Grufity logoGrufity logo

IBIO

1.70USD+0.10(+6.25%)Market Closed

Ibio Inc

Market Summary

USD1.70+0.10Market Closed
6.25%

IBIO Stock Price

RSI Chart

Valuation

Market Cap

458.1M

Price/Earnings

-13.56

Price/Sales

44.06

Price/Cashflow

-13.54

Price/Sales

Profitability

Return on Equity

-41.74%

Return on Assets

-28.72%

Fundamentals

Revenue

Revenue Y/Y

153.99%

Revenue Q/Q

1.1K%

Earnings

Earnings (TTM)

-56.6M

Earnings Y/Y

-102.82%

Earnings Q/Q

-46.33%

Price Action

52 Week Range

1.4618.75
(Low)(High)

Last 7 days

4.3%

Last 30 days

-17.5%

Last 90 days

-76.1%

Trailing 12 Months

-90.7%

Financial Health

Current Ratio

7.28

Investor Care

Buy Backs (1Y)

95.88%

Diluted EPS (TTM)

-2.88

Peers (Alternatives to Ibio)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
6.86% 46.41%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
14.32% 33.87%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
22.70% -39.52%
4.2
2.57
227.55% 302.16%
41.3B
10.4B
7.38% 30.80%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
3.89% 57.25%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
6.18% -26.69%
-12.87
32.5
-41.50% -607.58%
3.4B
-
7.39% -35.47%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
4.34% -60.25%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
45.87% -20.63%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
1.8B
-19.41% -89.80%
-1.22
1.39
53.41% -22.97%
1.6B
69.7M
-4.82% -76.34%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
5.78% -29.88%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-14.32% -56.80%
-4.02
6.06
-17.11% -27.41%
458.1M
-
-17.48% -90.68%
-13.56
44.06
522.71% -129.91%
218.9M
-
-15.58% -80.57%
-2.36
609.63
-71.03% -64.56%

Financials for Ibio

Income Statement (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q12021Q42021Q32021Q2
RevenueNaN%nullnullnullnull10,200
Gross Profit202.4%2,4258021,241909
Operating Expenses-0.3%44,54144,65838,05634,40232,020
  S&GA Expenses-2.9%29,30130,16826,95524,39922,031
  R&D Expenses5.2%15,24014,49011,10110,2149,989
Net Income-70.8%-56,586.67-33,133.00-28,404.00-24,613.00-23,207.00
* denotes actual numbers (not divided by Thousands)
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-14.9%8599115126144
  Current Assets41.0%6445606790
    Cash Equivalents-56.4%1023343963
  Inventory65.3%321--
  Net PPE152.3%31353310
Liabilities0.8%3636363643
  Current Liabilities5.8%3230888
Shareholder's Equity-23.8%48637991101
  Retained Earnings-8.1%-242.06-223.93-206.88-194.49-182.57
  Additional Paid-In Capital1.1%291288286285283
Shares OutstandingInfinity%9-218218218
Minority InterestNaN%---0.02--
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q12021Q42021Q32021Q2
Cashflow From Operations-22.8%-40.79-33.20-34.61-32.34-30.06
  Share Based Compensation26.5%54322
Cashflow From Investing93.3%-0.57-8.51-13.04-25.03-26.48
Cashflow From Financing-103.4%-6.51-3.2024379

Risks

What is the probability of a big loss on IBIO?

100%


Probability that Ibio stock will be more than 20% underwater in next one year

100%


Probability that Ibio stock will be more than 30% underwater in next one year.

93.8%


Probability that Ibio stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does IBIO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Ibio was unfortunately bought at previous high price.

Returns

Cumulative Returns on IBIO

-36.9%


10-Year Cumulative Returns

-47.4%


7-Year Cumulative Returns

-48.1%


5-Year Cumulative Returns

-28.7%


3-Year Cumulative Returns

What are the long-term rolling returns for IBIO?

FIve years rolling returns for Ibio.

Which funds bought or sold IBIO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-
-
-%
2022-11-15
Clearstead Advisors, LLC
UNCHANGED
-
-
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SA
SOLD OFF
-100
-6,794
-
-%
2022-11-15
JANE STREET GROUP, LLC
ADDED
26.82
-1,000
5,000
-%
2022-11-15
STATE STREET CORP
UNCHANGED
-
-73,000
131,000
-%
2022-11-14
PRICE T ROWE ASSOCIATES INC /MD/
NEW
-
55,000
55,000
-%
2022-11-14
UNITED CAPITAL FINANCIAL ADVISERS, LLC
REDUCED
-7.05
-1,000
2,000
-%
2022-11-14
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
NEW
-
31,000
31,000
-%
2022-11-14
GOLDMAN SACHS GROUP INC
SOLD OFF
-100
-78,000
-
-%

1–10 of 44

Latest Funds Activity

Are funds buying IBIO calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own IBIO

Ibio News

MarketWatch

iBio CEO Thomas Isett Resigns.2 days ago

Marketscreener.com

IBIO Fair Value

Recent SEC filings of Ibio

View All Filings
Date Filed Form Type Document
Nov 15, 2022
4
Insider Trading
Nov 15, 2022
4
Insider Trading
Nov 14, 2022
10-Q
Quarterly Report
Nov 03, 2022
8-K
Current Report
Nov 03, 2022
8-K
Current Report
Oct 26, 2022
DEF 14A
DEF 14A
Oct 20, 2022
8-K
Current Report
Oct 14, 2022
8-K
Current Report
Oct 11, 2022
10-K
Annual Report
Oct 07, 2022
8-K
Current Report

Latest Insider Trading transactions for IBIO

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-11
Lutz Robert Matthew
ACQUIRED
-
-
100,057
See Remarks
2022-11-11
Brenner Martin
ACQUIRED
-
-
95,348
Chief Scientific Officer
2022-03-10
Lutz Robert Matthew
SOLD
-8,510.4
0.3456
-24,625
See Remarks
2021-03-04
Lutz Robert Matthew
ACQUIRED
-
-
232,000
See Remarks
2020-12-01
Maddux Randy Joe
ACQUIRED
-
-
309,000
Chief Operating Officer
2020-08-11
Eastern Capital LTD
SOLD
-46,330,400
2.9204
-15,864,400
-
2020-08-10
Eastern Capital LTD
SOLD
-28,429,600
3.9133
-7,264,860
-
2020-08-07
Eastern Capital LTD
SOLD
-5,185,580
3.8253
-1,355,600
-
2020-08-07
Eastern Capital LTD
ACQUIRED
5,785,000
0.2
28,925,000
-
2020-08-06
Eastern Capital LTD
SOLD
-11,570,500
4.1799
-2,768,140
-

1–10 of 23

Thomas F. Isett
80
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

IBIO Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Condensed Consolidated Statements of Operations and Comprehensive Loss  
Revenues$ 0$ 84
Operating expenses:  
Research and development2,5481,134
General and administrative (related party of $0 and $189)5,0884,175
Total operating expenses7,6365,309
Operating loss(7,636)(5,225)
Other income:  
Interest income9936
Consolidated net loss from continuing operations(7,537)(5,189)
Net loss attributable to noncontrolling interest01
Net loss attributable to iBio, Inc. from continuing operations(7,537)(5,188)
Preferred stock dividends- iBio CDMO Tracking Stock0(66)
Net loss attributable to iBio, Inc. stockholders from continuing operations(7,537)(5,254)
Loss from discontinued operations(10,593)(3,751)
Net loss available to iBio, Inc. stockholders(18,130)(9,005)
Comprehensive loss:  
Consolidated net loss(18,130)(8,940)
Other comprehensive loss - unrealized loss on debt securities(10)(1)
Comprehensive loss$ (18,140)$ (8,941)
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations$ (0.85)$ (0.60)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations(0.85)(0.60)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations(1.20)(0.43)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations(1.20)(0.43)
Loss per common share attributable to iBio, Inc. stockholders - basic - total(2.05)(1.03)
Loss per common share attributable to iBio, Inc. stockholders - diluted - total$ (2.05)$ (1.03)
Weighted-average common shares outstanding - basic8,8428,715
Weighted-average common shares outstanding - diluted8,8428,715

IBIO Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2022
Jun. 30, 2022
Current assets:  
Cash and cash equivalents$ 9,887,000$ 22,676,000
Investments in debt securities7,599,00010,845,000
Accounts receivable - trade1,055,0001,000,000
Settlement receivable - current portion5,100,0005,100,000
Prepaid expenses and other current assets1,146,0001,549,000
Current assets held for sale38,778,0003,900,000
Total Current Assets63,565,00045,070,000
Restricted cash5,996,0005,996,000
Noncurrent assets held for sale 37,314,000
Convertible promissory note receivable and accrued interest1,650,0001,631,000
Finance lease right-of-use assets, net of accumulated amortization875,00074,000
Operating lease right-of-use asset2,928,0003,068,000
Fixed assets, net of accumulated depreciation3,464,0001,373,000
Intangible assets, net of accumulated amortization6,013,0004,851,000
Prepaid expenses - noncurrent44,00074,000
Security deposits29,00029,000
Total Assets84,564,00099,406,000
Current liabilities:  
Accounts payable4,807,0004,264,000
Accrued expenses2,595,0003,764,000
Finance lease obligations - current portion303,00046,000
Operating lease obligation - current portion183,00091,000
Current liabilities related to assets held for sale1,949,00056,000
Term note payable - net of deferred financing costs22,201,00022,161,000
Contract liabilities161,000100,000
Total Current Liabilities32,199,00030,436,000
Finance lease obligations - net of current portion576,00030,000
Operating lease obligation - net of current portion3,421,0003,514,000
Noncurrent liabilities related to assets held for sale 1,971,000
Total Liabilities36,196,00035,921,000
iBio, Inc. Stockholders' Equity:  
Series 2022 Convertible Preferred Stock - $.001 par value; 1,000,000 shares authorized; 0 and 1,000 shares issued and outstanding as of September 30, 2022 and June 30, 2022, respectively
Common stock - $0.001 par value; 275,000,000 shares authorized at September 30, 2022 and June 30, 2022; 9,006,582 and 8,727,158 shares issued and outstanding as of September 30, 2022 and June 30, 2022, respectively9,0009,000
Additional paid-in capital290,642,000287,619,000
Accumulated other comprehensive loss(223,000)(213,000)
Accumulated deficit(242,060,000)(223,930,000)
Total iBio, Inc. Stockholders' Equity48,368,00063,485,000
Total Liabilities and Equity$ 84,564,000$ 99,406,000